Drug Trial Radar · NCT06499350
A Study of FC084CSA in Combination of Tislelizumab in Patients With Advanced Malignant Solid Tumors
Last checked: Nov 19, 2026Latest source record: Sep 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
33
Planned (sponsor's estimate)
Start
Nov 13, 2024
Primary completion
Dec 1, 2026
Study completion Dec 30, 2026
Sponsor
- Lead sponsor
- FindCure Biosciences (ZhongShan) Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jul 12, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to learn the safety, tolerability, pharmacokinetic characteristics and efficacy of FC084CSA in combination with Tislelizumab in patients with advanced malignant solid tumors.
Conditions
- Advanced Malignant Solid Tumors
Interventions
FC084CSA+Tislelizumab combination (dose escalation)Drug
Increasing dose levels of FC084CSA+fixed dose Tislelizumab combination therapy
RP2D of FC084CSA+Tislelizumab combination (dose expansion)Drug
RP2D of FC084CSA+fixed dose Tislelizumab combination therapy
Primary outcomes
What the sponsor says the trial is designed to measure.
- Determine the Maximum Tolerated Dose (MTD)Time frame: Approximately 8 months
- Determine the Recommended Phase 2 Dose (RP2D)Time frame: Approximately 8 months
- Determine dose-limiting toxicity (DLT)Time frame: 21 days after first dose
- Objective response rate (ORR)Time frame: Approximately 12 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Shanghai East Hospital
Shanghai, Shanghai Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.